Dual mRNA nanoparticles strategy for enhanced pancreatic cancer treatment and β-elemene combination therapy
Open Access
- 11 March 2025
- journal article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (11)
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is notoriously immune-resistant, limiting the clinical efficacy of single-agent immune modulators and thereby necessitating the exploration of multimodal immunotherapy combinations. Traditional approaches combining conventional immune checkpoint inhibitors with neoantigen vaccines have shown some promise in treating PDAC but are often compromised by intratumoral T lymphocyte exhaustion and systemic toxicity. Hence, novel approaches are needed to address these challenges. Herein, we demonstrate that mRNA polymeric nanoparticles encoding anti-PD-1 antibodies in situ at the tumor site enhance the therapeutic efficacy of neoantigen-based mRNA vaccine for PDAC. This mRNA-based, in situ anti-PD-1 antibody production strategy also protects tumor-infiltrating T cells from PD-1 inhibition, potentially reducing the toxicities induced by systemic checkpoint inhibition. Our study may provide an innovative dual mRNA nanoparticle strategy for effective tumor neoantigen immunotherapy, as well as an mRNA cancer combination therapy strategy with other clinically approved drugs (e.g., β-elemene).Keywords
This publication has 56 references indexed in Scilit:
- Therapeutic nucleic acids in regenerative medicine and tissue repairNano Research, 2024
- Nano-bio interactions in mRNA nanomedicine: Challenges and opportunities for targeted mRNA deliveryAdvanced Drug Delivery Reviews, 2023
- Cancer nanomedicine toward clinical translation: Obstacles, opportunities, and future prospectsMed, 2022
- Hallmarks of response, resistance, and toxicity to immune checkpoint blockadeCell, 2021
- Pancreatic CancerJAMA, 2021
- Looking to Long-term Survivors for Improved Pancreatic Cancer TreatmentJAMA, 2020
- A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder CancerCell, 2020
- Challenges and Opportunities for Pancreatic Cancer ImmunotherapyCancer Cell, 2020
- Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal AdenocarcinomaJAMA Oncology, 2019
- Checkpoint inhibitors in pancreatic cancerCancer Treatment Reviews, 2019